Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

Clinical trial NCT04197986 · TERMINATED

Trial details

NCT number: NCT04197986
Sponsor: QED Therapeutics, a BridgeBio company
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Upper Tract Urothelial Carcinomas Urothelial Bladder Cancer

Start date: 2020-03-11
Primary completion: 2023-02-28
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.